Elite Pharma Q2 FY2024 revenue $14.2M (+64.9% YoY); net income $14.9M (+886%)

ELITE PHARMACEUTICALS INC /NV/

2024-Q2 EPS reported $0.02 revenue$23,137,261

Consolidated revenue of $14.2M for Q2 ended Sep 30, 2023, up 64.9% YoY.
Operating profit of $1.9M, up 78.1% from prior-year period.
Net income attributable to common shareholders: $14.9M, an 886% increase.
Growth driven by launch of Elite Laboratories label product line in June 2023 quarter.
Conference call scheduled for Nov 15, 2023 at 11:30 AM EST.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ELITE PHARMACEUTICALS INC /NV/ reported the second quarter of fiscal year 2024 ended September 30, 2023 results: revenue $14.2 million, net income $14.9 million.

Period: the second quarter of fiscal year 2024 ended September 30, 2023
Revenue: $14.2 million
Net income: $14.9 million
Result: reported results

Exact text from the filing

Consolidated revenues for the three-month period ended September 30, 2023, were $14.2 million, an increase of $5.6 million or 64.9% as compared to the comparable period of the prior fiscal year.

View on SEC.gov

309 earnings releases filed in the last 30 days. Browse all earnings releases →

ELITE PHARMACEUTICALS INC /NV/ filing history →

Source: SEC EDGAR

accession 0001493152-23-041323

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.